Mechanism of iron toxicity

Food and Nutrition Bulletin

Volumn 28, Issue 4 SUPPL., 2007, Pages

  Hershko, Chaim ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Cytokines; Infection; Inflammation; Iron; NTBI

Indexed keywords

CONFERENCE PROCEEDING; DISEASE SEVERITY; HEALTH IMPACT; IRON; PHYSIOLOGICAL RESPONSE; TOXICITY;

EID: 38549164231     PISSN: 03795721     EISSN: None     Source Type: Journal    
DOI: 10.1177/15648265070284s403     Document Type: Conference Paper

References (90)

1. Halliwell B, Gutteridge JM. Biologically relevant metal ion-dependent hydroxyl radical generation. An update. FEBS Lett 1992;307:108-12.
2. Cadenas E. Biochemistry of oxygen toxicity. Annu Rev Biochem 1989;58:79-110.
3. Kadiiska MB, Burkitt MJ, Xiang QH, Mason RP. Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation. J Clin Invest 1995; 96:1653-7.
4. Richter C, Gogvadze V, Laffranchi R, Schlapbach R, Schweizer M, Suter M, Walter P, Yaffee M. Oxidants in mitochondria: From physiology to diseases. Biochim Biophys Acta 1995;1271:67-74.
5. Fry M, Green DE. Cardiolipin requirement by cytochrome oxidase and the catalytic role of phospholipid. Biochem Biophys Res Commun 1980;93:1238-46.
6. Goormaghtigh E, Brasseur R, Ruysschaert JM. Adriamycin inactivates cytochrome C oxidase by exclusion of the enzyme from its cardiolipin essential environment. Biochem Biophys Res Commun 1982;104:314-20.
7. Houglum K, Filip M, Witztum JL, Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest 1990;86:1991-8.
8. Stadtman ER. Metal ion-catalyzed oxidation of proteins: Biochemical mechanism and biological consequences. Free Radic Biol Med 1990;9:315-25.
9. Heales SJ, Davies SE, Bates TE, Clark JB. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res 1995;20:31-8.
10. Zager A. Mitochondrial free radical production induces lipid peroxidation during myohemoglobinuria. Kidney Int 1996;49:741-51.
11. Pitkainen S, Robinson BH. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest 1996;98:345-51.
12. Rothman RJ, Serroni A, Farber JL. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury. Mol Pharmacol 1992;42:703-10.
13. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: The control of cellular iron metabolism. Cell 1993;72:19-28.
14. Breuer W, Epsztejn S, Cabantchik ZI. Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Lett 1996;382:304-8.
15. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J Haematol 1978;40:255-63.
16. Singh S, Hider RC, Porter JB. A direct method for quantification of non-transferrin bound iron (NTBI). Anal Biochem. 1990;186:320-3.
17. Anuwatanakulchai M, Pootrakul P, Thuvasethakul P, Wasi P. Non-transferrin plasma iron in β-thalassaemia/HbE and haemoglobin H diseases. Scand J Haematol 1984;32:153-8.
18. Wagstaff M, Peters SW, Jones BM, Jacobs A. Free iron and iron toxicity in iron overload. Br J Haematol 1985; 61:566-7.
19. Gutteridge JM, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci (Lond) 1985;68:463-7.
20. al-Refaie FN, Wickens DG, Worike B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol 1992;82:431-6.
21. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996;88:705-13.
22. Link G, Pinson A, Hershko C. Heart cells in culture: A model of myocardial iron overload and chelation. J Lab Clin Med 1985;106:147-53.
23. Randell EW, Parkes JG, Olivieri NF, Templeton DM. Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron. J Biol Chem 1994;269:16046-53.
24. Le Lan C, Lorial O, Cohen T, Ropert M, Glickstein H, Lainé F, Pouchard M, Deugnier Y, Le Treut A, Breuer W, Cabantchik ZI, Brissot P. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005;105:4527-31.
25. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with desferrioxamine: Indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003;101:4632-9.
26. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: A study in adult patients with acquired anemias. Blood 2003;101:91-6.
27. Mak IT, Weglicki WB. Characterization of iron-mediated peroxidative injury in isolated hepatic lysosomes. J Clin Invest 1985;75:58-63.
28. Seymour CA, Peters TJ. Organelle pathology in primary and secondary haemochromatosis with special reference to lysosomal changes. Br J Haematol 1978;40:239-53.
29. Link G, Pinson A, Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med 1993; 121:127-34.
30. Bacon BR, O'Neill R, Britton RS. Hepatic mitochondrial energy production in rats with chronic iron overload. Gastroenterology 1993;105:1134-40.
31. Ceccarelli D, Gallesi D, Giovannini F, Ferrali M, Masini A. Relationship between free iron level and rat liver mitochondrial dysfunction in experimental dietary iron overload. Biochem Biophys Res Commun 1995;209:53-9.
32. Link G, Saada A, Pinson A, Konijn AM, Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med 1998; 131:466-74.
33. Robinson BH, Glerum DM, Chow W, Petrova-Benedict R, Lightowlers R, Capaldi R. The use of skin fibroblast cultures in the detection of respiratory chain defects in patients with lactic acidemia. Pediatr Res 1990;28:549-55.
34. Hatefi Y. Preparation and properties of NADH:ubiquinone oxidoreductase (complex I) ECI6.5.3. Methods Enzymol 1978;53:11-4.
35. Zhang Y, Marcillat O, Giulivi C, Ernster L, Davies KJ. The oxidative inactivation of mitochondrial electron transport chain components and ATPase. J Biol Chem 1990;265:16330-6.
36. McKnight RC, Hunter FE Jr. Mitochondrial membrane ghosts produced by lipid peroxidation induced by ferrous ion. II. Composition and enzymatic activity. J Biol Chem 1966;241:2757-65.
37. 2+ cycling and membrane damage during tert-butyl hydroperoxide metabolism by rat-liver mitochondria. Eur J Biochem 1984;140:1-6.
38. 2+ from rat liver mitochondria. Eur J Biochem 1985;149:633-9.
39. Lotscher HR, Winterhalter KH, Carafoli E, Richter C. Hydroperoxides can modulate the redox state of pyridine nucleotides and the calcium balance in rat liver mitochondria. Proc Natl Acad Sci USA 1979;76:4340-4.
40. Lotscher HR, Winterhalter KH, Carafoli E, Richter C. Hydroperoxide-induced loss of pyridine nucleotides and release of calcium from rat liver mitochondria. J Biol Chem 1980;255:9325-30.
41. 2+ release from mitochondria by the oxidation-reduction state of pyridine nucleotides. Proc Natl Acad Sci USA 1978;75:1690-4.
42. 2+-induced permeabilization of rat liver mitochondria. Biochem J 1986;239:19-29.
43. 2+ overload. Eur J Biochem 1988;178:489-501.
44. Bellomo G, Jewell SA, Orrenius S. The metabolism of menadione impairs the ability of rat liver mitochondria to take up and retain calcium. J Biol Chem 1982; 257:11558-62.
45. Frei B, Winterhalter KH, Richter C. Mechanism of alloxan-induced calcium release from rat liver mitochondria. J Biol Chem 1985;260:7394-7401.
46. Link G, Pinson A, Kahane I, Hershko C. Iron loading modifies the fatty acid composition of cultured rat myocardial cells and liposomal vesicles: Effect of ascorbate and α-tocopherol on myocardial lipid peroxidation. J Lab Clin Med 1989;114:243-9.
47. Heys AD, Dormandy TL. Lipid peroxidation in iron loaded spleens. Clin Sci (Lond) 1981;60:295-301.
48. O'Connell MJ, Ward RJ, Baum H, Peters TJ. The role of iron in ferritin- and haemosiderin-mediated lipid peroxidation in liposomes. Biochem J 1985;229:135-9.
49. Nienhuis AW. Vitamin C and iron. N Engl J Med 1981;304:170-1.
50. Hershko C, Link G, Pinson A. Modification of iron uptake and hpid peroxidation by hypoxia, ascorbic acid, and α-tocopherol in iron-loaded rat myocardial cell cultures. J Lab Clin Med 1987;110:355-61.
51. Moreb J, Hershko C, Hasin Y. Effects of acute iron loading on contractility and spontaneous beating rate of cultured rat myocardial cells. Basic Res Cardiol 1988;83:360-8.
52. US Food and Drug Administration. Preventing iron poisoning in children. FDA Backgrounder, 15 January 1997.
53. Covey TJ. Ferrous sulfate poisoning: A review, case summaries and therapeutic regimen. J Pediatr 1964;64:218-26.
54. Stein M, Blayney D, Feit T, Goergen TG, Micik S, Nyhan WL. Acute iron poisoning in children. West J Med 1976;125:289-97.
55. Reynolds LG. Diagnosis and management of acute iron poisoning. Baillieres Clin Haematol 1989;2:423-33.
56. Singhi SC, Baranwal AK. Acute iron poisoning: Clinical picture, intensive care needs and outcome. Indian Pediatr 2003;40:1177-82.
57. Peto TE, Thompson J. A reappraisal of the effect of iron and desferrioxamine on the growth of Plasmodium falciparum in vitro: The unimportance of serum iron. Br J Haematol 1986;63:273-80.
58. Raventos-Suarez C, Pollack S, Nagel RL. Plasmodium falciparum: Inhibition of in vitro growth by desferrioxamine. Am J Trop Med Hyg 1982;31:919-22.
59. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graslund A, Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 1993;268:26200-5.
60. Hershko C, Peto TE. Deferoxamine inhibition of malaria is independent of host iron status. J Exp Med 1998;168:375-87.
61. Bienzle U, Fritsch KG, Hoth G, Rozdzinski E, Köhler K, Kalinowski M, Kremsner P, Rosenkaimer F, Feldmeier H. Inhibition of Plasmodium vinckei-malaria in mice by recombinant murine interferon-gamma. Acta Trop 1988; 45:289-90.
62. Yinnon AM, Theanacho EN, Grady RW, Spira DT, Hershko C. Antimalarial effect of HBED and other phenolic and catecholic iron chelators. Blood 1989;74:2166-71.
63. Heppner DG, Hallaway PE, Kontoghiorghes GJ, Eaton TW Antimalarial properties of orally active iron chelators. Blood 1998;72:358-61.
64. Clarke CJ, Eaton JM. Hydrophobic iron chelators as new antimalarial drugs. Clin Res 1990;38:300A.
65. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI. Mode of action of iron (III) chelators as anti-malarials. IV. Potentiation of desferal action by benzoyl and isonicotinoyl hydrazone derivatives. J Lab Clin Med 1996;127:574-82.
66. Gordeuk VR, Thuma PE, Brittenham GM, Zulu S, Simwanza G, Mhangu A, Flesch G, Parry D. Iron chelation with deferoxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 1992;79:308-12.
67. Gordeuk VR, Thuma PE, Brittenham GM, Biemba G, Zulu S, Simwanza G, Kalense P, M'hango A, Parry D, Poltera AA, Aikawa M. Iron chelation. as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg 1993;48:193-7.
68. Bunnag D, Poltera AA, Viravan C, Looareesuwan S, Harinasuta T, Schindléry C. Plasmodicidal effect of desferrioxamine B in human vivax or falciparum malaria from Thailand. Acta Trop 1992;52:59-67.
69. Thuma PE, Olivieri NF, Mabeza GF, Biemba G, Parry D, Zulu S, Fassos FF, McClelland RA, Koren G, Brittenham GM, Gordeuk VR. Assessment of the effect of the oral iron chelator deferiprone on mild Plasmodium falciparum parasitema in humans. Am J Trop Med Hyg 1998;58:358-64.
70. Gordeuk VR, Thuma PE, Brittenham GM, McLaren C, Parry D, Backenstose AR, Biemba G, Msiska R, Holmes L, McKinley E, Vargas L, Gilkeson RC, Poltera AA. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 1992;327:1473-7.
71. Thuma PE, Mabeza GF, Biemba G, Bhat GJ, McLaren C, Moyo VM, Zulu S, Khumalo H, Mabeza P, M'hango A, Parry D, Poltera AA, Brittenham GM, Gordeuk VR. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans R Soc Trop Med Hyg 1998;92:214-8.
72. Mohanty D, Ghosh K, Pathare AV, Karnad D. Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria. Indian J Med Res 2002;115:17-21.
73. Smith HJ, Meremikwu M. Iron chelating agents for treating malaria. Cochrane Database Syst Rev 2003; (2):CD0014174.
74. Aikawa M, Wernsdorfer WH, McGregor I, Livingstone C, Edinburgh. Fine structure of malaria parasites in the various stages of development. In: Scheibel LW, Sherman IW, eds. Principles and practice of malariology. Edinburgh, UK: Churchill Livingstone, 1988;97-130.
75. Slater AF, Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature 1992;355:167-9.
76. Pouvelle B, Spiegel R, Hsiao L, Howard RJ, Morris RL, Thomas AP, Taraschi TF. Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature 1991;353:73-5.
77. Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI. The antimalarial action of Desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J Clin Invest 1993;91:218-24.
78. Pollack S, Schnelle V. Inability to detect transferrin receptors on P. falciparum parasitized red cells. Br J Haematol 1988;68:125-9.
79. Sanchez-Lopez R, Haldar K. A transferrin-independent iron uptake activity in Plasmodium falciparum-infected and uninfected erythrocytes. Mol Biochem Parasitol 1992;55:9-20.
80. Gabay T, Ginsburg H. Haemoglobin denaturation and iron release in acidified red blood cell lysate - A possible source of iron for intraerythrocytic malaria parasites. Exp Parasitol 1993;77:261-72.
81. Loyevsky M, John C, Dickens B, Hu V, Miller JH, Gordeuk VR. Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators. Mol Biochem Parasitol 1999;101:43-59.
82. Oppenheimer SJ. Iron and its relation to immunity and infectious disease. J Nutr 2001;131:616S-35S.
83. Hershko C. Iron, infection and immune function. Proc Nutr Soc 1993;52:165-74.
84. Gera T, Sachdev HP. Effect of iron supplementation on incidence of infectious illness in children: Systematic review. BMJ 2002;325:1142.
85. Tielsch JM, Khatry SK, Stoltzfus RJ, Katz J, LeClerq SC, Adhikari R, Mullany LC, Shresta S, Black RE. Effect of routine prophylactic supplementation with iron and folic acid on preschool child mortality in southern Nepal: Community-based, cluster-randomised, placebo-controlled trial. Lancet 2006;367:144-52.
86. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, Dhingra U, Kabole I, Deb S, Othman MK, Kabole FM. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet 2006;367:133-43.
87. Mulero V, Brock JH. Disturbance in iron homeostasis. In: Weiss G, Gordeuk VR, Hershko C, eds. Anemia of chronic disease. Boca Raton, Fla, USA: Taylor & Francis, 2005:105-26.
88. Jason J, Archibald LK, Nwanyanwu OC, Bell M, Buchanan I, Larned J, Kazembe PN, Dobbie H, Parekh B, Byrd MG, Eick A, Han A, Jarvis WR. Cytokines and malaria parasitemia. Clin Immunol 2001; 100:208-18.
89. Nyakeriga AM, Williams TN, Marsh K, Wambua S, Perlmann H, Perlmann P, Grandien A, Troye-Blomberg M. Cytokine mRNA expression and iron status in children living in a malaria endemic area. Scand J Immunol 2005;61:370-5.
90. Nyakeriga AM, Troye-Blomberg M, Chemtai AK, Marsh K, Williams TN. Malaria and nutritional status in children living on the coast of Kenya. Am J Clin Nutr 2004;80:1604-10.